Join to access to all OVN content. Join for Free
Professional Development: Why Consider an Executive Coach
Life Reset Labs Dana Paskalis coaching in professional development career coaching executive coach advice

Professional Development: Why Consider an Executive Coach


Share This Article


Summary

In this episode, Dana Paskalis, founder of Life Reset Labs, joins to discuss the pivotal role of coaching in personal and professional development. Dana outlines her career path leading to the creation of her coaching company and highlights the significance of self-talk and mindset in advancing one's career. She explores the differences between a mentor and a coach, offering advice on when to seek professional guidance. The conversation also covers the impact of company culture and handling layoffs, alongside strategies for proactive career planning. The episode concludes with a reminder to subscribe for more insights.

Today’s guest is Dana Paskalis, CEO and Founder of Life Reset Labs and we discuss why professionals should consider an executive or career coach
Dana discusses….

👉 What led her to transition to a Certified Coach and Life Strategist
👉 What exactly a Certified Coach and Life Strategist does
👉 What is the difference between a coach and a mentor
👉 Who should consider a coach (and who doesn’t need a coach)
👉 Tips and career advice for MSLs
👉 Tips and advice for finding success in 2023

Click for Source
Life Reset Labs, Dana Paskalis, coaching in professional development, career coaching, executive coach advice

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Article
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Explore OVN